JGC
ANTH

J. Goldman & Co’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

J. Goldman & Co’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-15,625
Closed -$463K – 365
2013
Q2 		$463K Buy
+15,625
New +$583K 0.05% 214

Other funds holding ANTH

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

J. Goldman & Co's ANTH Position: Q3 2013 in Review

J. Goldman & Co sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q3 2013, closing a stake of 15,625 shares — an estimated $463K sold.

J. Goldman & Co first reported a position in ANTH in Q2 2013 and held it in 1 quarter. The position peaked at $463K in Q2 2013. 32 funds tracked by Wall St. Rank hold ANTH as of Q3 2013.

  • J. Goldman & Co reported no remaining Anthera Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • J. Goldman & Co sold 15,625 Anthera Pharmaceuticals, Inc. shares in Q3 2013, an estimated $463K.
  • J. Goldman & Co first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • J. Goldman & Co's Anthera Pharmaceuticals, Inc. position peaked at $463K in Q2 2013.
  • 32 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2013.

Based on J. Goldman & Co's 13F filing for Q3 2013, filed 14 Nov 2013.